Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer

Keyphrases

• Chemotherapy Regimen 100%
• Non-muscle Invasive Bladder Cancer (NMIBC) 100%
• MMC 100%
• Mitomycin C 100%
• Intravesical Gemcitabine 100%
• Gemcitabine 60%
• Intravesical 60%
• BCG Refractory 60%
• Combination Chemotherapy 40%
• Recurrence Rate 40%
• Sterile Water 40%
• Demographic Information 20%
• Lower Urinary Tract Symptoms 20%
• Patient Demographics 20%
• Induction Therapy 20%
• Bladder Cancer 20%
• Rash 20%
• Biopsy-proven 20%
• Median Time 20%
• Cystectomy 20%
• Side Effect Profile 20%
• Major Complications 20%
• Cystoscopy 20%
• Irritative 20%
• Intravesical Therapy 20%
• Benadryl 20%
• Recurrence-free 20%
• Disease Information 20%
• Number of Patients 20%
• Intolerant 20%

Medicine and Dentistry

• Chemotherapy 100%
• Gemcitabine 100%
• Non Muscle Invasive Bladder Cancer 100%
• Mitomycin 100%
• Recurrent Disease 66%
• Mycobacterium Bovis BCG 50%
• Combination Chemotherapy 33%
• Sterile Water 33%
• Cytotechnology 16%
• Lower Urinary Tract Symptom 16%
• Bladder Cancer 16%
• Cystoscopy 16%
• Cystectomy 16%
• Exanthem 16%
• Side Effect 16%
• Biopsy Technique 16%
• Intravesical Drug Administration 16%
• Diphenhydramine 16%
• Diseases 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Mitomycin 100%
• Non Muscle Invasive Bladder Cancer 100%
• Gemcitabine 100%
• Recurrent Disease 66%
• Mycobacterium Bovis BCG 50%
• Sterile Water 33%
• Bladder Cancer 16%
• Side Effect 16%
• Rash 16%
• Diphenhydramine 16%
• Lower Urinary Tract Symptom 16%
• Diseases 16%